Genoscience Pharma Is Innovating to Disrupt Cancer Treatment

We are conceptualizing and developing disruptive and innovative science from bench to bedside for improving the conditions of patients in serious unmet medical needs.

Learn More

Our Approach

As all human living cells, cancer cells need energy to self-renew and survive. Lysosome is a key compartment implicated in cancer cells survival. Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosome a target of interest for novel therapies. Genoscience Pharma focuses on new approaches based on the depriving of cancer cells from essential nutrients by disrupting lysosomal functions.

Discover

Our Pipeline

We leverage our deep knowledge of underlying biological processes to develop innovative and disruptive technology, with potent small molecule drug candidates that directly target lysosomal functions, implicated in the growth, spread and resistance of cancers. We retain global development and commercialization rights of GNS561.

Discover

News

News
Nov. 18, 2020

GNS561’s successful phase 1b trial completed

Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
News
July 22, 2020

GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
News
18 June, 2020

Our COVID-19 research Project supported by the French Government

Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
View All News

Events

Events
November 19-20, 2020

2020 Drugging Autophagy Summit

Genoscience Pharma has presented at The Drugging Autophagy Summit its Phase 1b results, where all…
Read More
Events
June 22-24, 2020

AACR 2020 Virtual Annual Meeting

GENOSCIENCE PHARMA Announces Remarkable Data on GNS561 in Combination with anti-PD1 to be Presented at…
Read More
Events
January 13-15, 2020

Biotech Showcase™ 2020

Biotech Showcase™ 2020 - San Francisco, California Investor conference   We will be present during…
Read More
View All Events

“Translating novel scientific insights into medicines for cancer patients”

Philippe Halfon, CEO of Genoscience Pharma